ArticleMolecular medicine reports2016
Suppression of A549 cell proliferation and metastasis by calycosin via inhibition of the PKC-α/ERK1/2 pathway: An in vitro investigation.
Article in Molecular medicine reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Molecular Dynamics-Guided Repositioning of FDA-Approved Drugs for PD-L1 Inhibition with In Vitro Anticancer Potential.International journal of molecular sciences · 2025Article
- Antiangiogenesis Roles of Exosomes with Fei-Liu-Ping Ointment Treatment are Involved in the Lung Carcinoma with the Lewis Xenograft Mouse Model.Evidence-based complementary and alternative medicine : eCAM · 2020Article
- An Integrated Strategy for Effective-Component Discovery of Astragali Radix in the Treatment of Lung Cancer.Frontiers in pharmacology · 2020Article
- Feifukang ameliorates pulmonary fibrosis by inhibiting JAK-STAT signaling pathway.BMC complementary and alternative medicine · 2018Article
- Calycosin improves cognitive function in a transgenic mouse model of Alzheimer's disease by activating the protein kinase C pathway.Neural regeneration research · 2017Article
Corrections and comments
- Erratum for
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mol Med Rep 12:[Related article:] 7992–8002, 2015; DOI: 10.3892/mmr.2015.4449 Following the publication of this article, an interested reader drew to our attention an anomaly associated with the presentation of Fig. 2; essentially, an image had been inadvertently selected from the same original photomicrograph to represent Fig. 2D, the centre panel [+80 nM phorbol-12-myristate-13-acetate (TPA), + 20 μM calycosin (Cal)] and Fig. 2F, the second panel from the right (+ 80 nM TPA, + 30 μM Cal). After having re-examined our original data, the panel originally featured in Fig. 2F was identified as having been selected incorrectly for the Figure. A corrected version of Fig. 2 is presented on next page, which features the proper data for Fig. 2F. Fig. 2D and F showed the effect of different concentrations of Cal on the migration and invasive ability of the TPA-treated A549 cells, respectively; Cal was demonstrated to inhibit the migration, and to suppress the invasive ability, of the A549 cells induced by TPA. Therefore, this error did not affect the overall conclusions reported in the present study. We sincerely apologize for this mistake, and thank the reader of our article who drew this matter to our attention. Furthermore, we regret any inconvenience this mistake has caused.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.